Table 2.
Demographic and Clinical Data of Patients With PD With Different Cognitive Status and Controls.a
| Control (n = 21) | PD-CogNL (n = 24) | PD-MCI (n = 30) | PD-D (n = 10) | P Value | |
|---|---|---|---|---|---|
| Male, no of patients | 10 | 14 | 15 | 5 | NS |
| Mean ± SD | |||||
| Age, years | 60.1 ± 13.6 | 62.1 ± 8.6 | 65.1 ± 11.8 | 69.0 ± 9.7 | NS |
| Education, years | 8.57 ± 4.68 | 10.39 ± 4.9 | 8.0 ± 3.0 | 7.6 ± 4.3 | NS |
| Disease duration, years | − | 4.7 ± 3.4 | 5.1 ± 2.9 | 6.8 ± 6.86 | NS |
| UPDRS motor score | − | 30.2 ± 12.2 | 42.4 ± 14.0b | 56.0 ± 15.3b,c | <.001 |
| Hoehn-Yahr stage | − | 2.2 ± 0.8 | 2.8 ± 0.7b | 3.7 ± 0.9b,c | <.001 |
| Madopar equivalent dose, mg | − | 299.5 ± 122.5 | 477.1 ± 82.9b,c | 581.3 ± 137.6b,c | <.001 |
Abbreviations: PD-CogNL, Parkinson’s disease with normal cognitive function; PD-MCI, Parkinson’s disease with mild cognitive impairment; PD-D, Parkinson’s disease with dementia; UPDRS, Unified Parkinson’s Disease Rating Scale; NS, nonsignificant; SD, standard deviation.
a Statistical comparisons were made using 1-way ANOVA, Fisher least significant difference t test was used for post hoc analysis. P > .05 was considered nonsignificant.
b P < .05, compared to PD-CogNL.
c P < .05, compared to PD-MCI.